Neoplasm
Conditions
Keywords
Advanced cancer, solid tumors, PI3K, mTOR, PI3K/mTOR, metastatic, Triple Negative Breast Cancer (TNBC)
Brief summary
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).
Interventions
DRUGPF-05212384 (gedatolisib)
PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
DRUGDocetaxel
Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
DRUGCisplatin
Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
DRUGDacomitinib
Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
Sponsors
Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Cisplatin Combination Expansion: Arm 1:Patients with TNBC with no prior cytotoxic chemotherapy therapy in the metastatic setting; Arm 2: Patients with TNBC and one or two prior cytotoxic therapies in the metastatic setting. * Arm A: castrate resistant prostate cancer, advanced breast cancer, or non-small cell lunch cancer that are candidates for treatment with a docetaxel-based combination. * Arm B: Urothelial transitional cell cancer, triple negative breast cancer, ovarian cancer or non small cell lunch cancer that are candidates for a cisplatin-based combination. * Arm C: Her2+ breast cancer refractory to prior herceptin or lapatinib, her2+ esophagal-gastric cancer, head and neck squamous cell cancer, or non small cell lunch cancer that are candidates for treatment with a dacomitinib-based combination. * Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not available. * Eastern Cooperative Oncology Group \[ECOG\] performance must be 0 or 1. * Adequate bone marrow, renal and liver function.
Exclusion criteria
* Prior therapy for Cisplatin Combination Expansion: * Prior platinum (carboplatin or cisplatin) in either the adjuvant or metastatic setting; * Prior radiation to \>25% bone marrow as estimated by the Investigator. * Patients with known symptomatic brain metastases. * Chemotherapy, radiotherapy, biologics or investigational agent within 4 weeks of the lead-in dose. * Major surgery within 4 weeks of the baseline disease assessments. * \>2 prior regimens containing cytotoxic chemotherapy in the metastatic setting. * Active bacterial, fungal or viral infection. * Uncontrolled or significant cardiovascular disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Up to 21 days | DLT was defined as any of the following adverse events (AEs) attributable to the combination: (1) hematologic: grade 4 neutropenia lasting \>7 days; febrile neutropenia; grade \>=3 neutropenia with infection; grade 3 thrombocytopenia with bleeding; grade 4 thrombocytopenia; (2) non-hematologic: grade \>=2 pneumonitis; grade\>=3 toxicities, except pneumonitis, and excluding those that had not been maximally treated; persistent, intolerable toxicities which resulted in the failure to deliver at least 3 of the 4 doses of PF-05212384 for Arms A and B or at least 3 of the 4 doses of PF-05212384 and 75% of dacomitinib for Arm C during the first cycle; the persistent, intolerable toxicities which result in delay of the start of the second cycle by more than 2 weeks relative to the scheduled start; in an asymptomatic participant, the grade 3 QTc prolongation persists after correction of any reversible causes. |
| Percentage of Participants With Objective Response - Arm B Expansion | Cycle 1 Day 1 up to 18 months | Percentage of participants with objective response based on the assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm) and no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease and no new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion. | Laboratory abnormalities were graded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Following parameters were analyzed for laboratory examination: anemia,hemoglobin increased, platelets, white blood cells, absolute neutrophils,lymphocyte count increased, lymphopenia. |
| Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion. | Laboratory abnormalities were graded per NCI CTCAE version 4.03 (Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Following parameters were analyzed for laboratory examination: partial thromboplastin time and prothrombin time international normalized ratio(INR). |
| Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion. | Laboratory abnormalities were graded per NCI CTCAE version 4.03 (Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Following parameters were analyzed for laboratory examination: alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), total bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. |
| Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion. | Laboratory abnormalities were graded per NCI CTCAE version 4.03 (Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Following parameter was analyzed for laboratory examination: urine protein. |
| Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | From baseline up to follow up (at least 28 days and no more than 35 days after discontinuation of treatment). Maximum duration between first and last dose: 842 days. | Blood pressure (BP), including systolic BP (SBP) and diastolic BP (DBP), and pulse rate were recorded in sitting position. |
| Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 7 days prior to Cycle 1 Day 1 for Arms A and B; pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 14 days prior to Cycle 1 Day 1 for Arm C. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 1 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 2 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 1 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 2 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1. | Cmax is defined as maximum observed plasma concentration. |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 7 days prior to Cycle 1 Day 1 for Arms A and B; pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 14 days prior to Cycle 1 Day 1 for Arm C. | AUClast is defined as area under the curve from time zero to last quantifiable concentration. |
| Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1. | AUCtau is defined as area under the concentration-time profile from time 0 to time tau. |
| Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 7 days prior to Cycle 2 Day 1. | AUCtau is defined as area under the concentration-time profile from time 0 to time tau. |
| Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1. | AUCtau is defined as area under the concentration-time profile from time 0 to time tau. |
| Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 1 Day 1. | AUCtau is defined as area under the concentration-time profile from time 0 to time tau. |
| Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 2 Day 1. | AUCtau is defined as area under the concentration-time profile from time 0 to time tau. |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1. | AUClast is defined as area under the curve from time zero to last quantifiable concentration. |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Docetaxel in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1. | AUClast is defined as area under the curve from time zero to last quantifiable concentration. |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 1 Day 1. | AUClast is defined as area under the curve from time zero to last quantifiable concentration. |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 2 Day 1. | AUClast is defined as area under the curve from time zero to last quantifiable concentration. |
| Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1. | AUCtau is defined as area under the concentration-time profile from time 0 to time tau. |
| Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1. | AUCtau is defined as area under the concentration-time profile from time 0 to time tau. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 7 days prior to Cycle 1 Day 1 for Arms A and B; pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 14 days prior to Cycle 1 Day 1 for Arm C. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 1 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 2 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 1 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 2 Day 1. | Tmax is defined as time to reach maximum observed plasma concentration. |
| Mean Serum Biomarkers for Glucose - Baseline | Baseline | A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This study employed metabolic biomarkers such as glucose as pharmacodynamics markers for dual PI3K/mTOR inhibition. |
| Mean Serum Biomarkers for Glucose - End of Treatment | End of treatment. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion. | A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This studies employed metabolic biomarkers such as glucose as pharmacodynamics markers for dual PI3K/mTOR inhibition. |
| Mean Serum Biomarkers for Insulin - Baseline | Baseline | A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This studies employed metabolic biomarkers such as insulin as pharmacodynamics markers for dual PI3K/mTOR inhibition. |
| Mean Serum Biomarkers for Insulin - End of Treatment | End of treatment. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion. | A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This studies employed metabolic biomarkers such as insulin as pharmacodynamics markers for dual PI3K/mTOR inhibition. |
| Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | Baseline | A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This studies employed metabolic biomarkers such as hemoglobin A1c (HbA1c) as pharmacodynamics markers for dual PI3K/mTOR inhibition. |
| Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | End of treatment. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion. | A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This studies employed metabolic biomarkers such as hemoglobin A1c (HbA1c) as pharmacodynamics markers for dual PI3K/mTOR inhibition. |
| Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | Baseline | Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP. |
| Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | Baseline | Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP. |
| Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | Baseline | Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP. |
| Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | Baseline | Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation category was BRAF mutation status. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP. |
| Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | Baseline | Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP. |
| Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | Baseline | Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP. |
| Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | Baseline | Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP. |
| Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | Baseline | Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP. |
| Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Baseline, Cycle 1 Day 1 (for Arm B Expansion), Cycle 1 Day 2 (for Arms A, B and C), Cycle 2 Day 1 (for Arms A, B and C), Day 1 for each cycle (Cycles 3-36, for Arms B Expansion and C) and end of treatment (up to 2 years, for Arms B Expansion and C). | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized. |
| Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Baseline, Cycle 1 Day 1 (for Arm B Expansion), Cycle 1 Day 2 (for Arms A, B and C), Cycle 2 Day 1 (for Arms A, B and C), Day 1 for each cycle (Cycles 3-36, for Arms B Expansion and C) and end of treatment (up to 2 years, for Arms B Expansion and C). | QT interval corrected using Fridericia's formula (QTcF) and Bazette's formula (QTcB): QT interval (time corresponding to the beginning of depolarization to re-polarization of the ventricles) divided by cube root of RR interval. Maximum QTcF was categorized as less than (\<) 450 milliseconds (msec), 450 msec to 480 msec, 480 msec to 500 msec, and more than (\>) 500 msec. |
| Percentage of Participants With Objective Response - Arm A | Baseline up to 18 months. | Percentage of participants with objective response based on the assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm) and no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease and no new lesions. |
| Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion. | An adverse event (AE) was any untoward medical occurrence in a clinical investigation participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. Treatment Emergent AEs were those occurred for the first time after the start of study treatment and within 28 days after final dose of study treatment and was not seen prior to the start of treatment, or those were seen prior to the start of study treatment but increased in Common Terminology Criteria for Adverse Events (CTCAE) grade after the start of study treatment and within 28 days after final dose of study treatment. AEs were graded by the investigator according to the CTCAE version 4.03 : Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE. |
| Percentage of Participants With Objective Response - Arm C | Baseline up to 18 months. | Percentage of participants with objective response based on the assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm) and no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease and no new lesions. |
| Clinical Benefit Response Rate - Arm B Expansion | Baseline up to 18 months. | Percent of participants with confirmed complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks on study according to Response Evaluation Criteria in Solid Tumors (RECIST). Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm) and no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease and no new lesions. SD was defined as not qualifying for CR, PR, Progressive Disease (PD). |
| Duration of Response - Arm B Expansion | Baseline up to 18 months. | Duration of response was calculated from first date of partial response (PR) or complete response (CR) to the date of progression or death due to any cause. In the event of no progression or death, the last tumor assessment date without progression was used in this calculation. |
| Progression Free Survival - Arm B Expansion | Baseline up to 18 months. | Progression free survival (PFS) defined as the time from first dose of study treatment to date of first documentation of progression or death due to any cause, whichever occurs first. PFS was calculated as first event date minus the date of first dose of study medication plus 1 . Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was Death). |
| Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Baseline, Day 1 and Day 8 of Cycles 1 and 2, Day 1 of Cycles 3 to 16. | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. |
| Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Baseline, Day 1 and Day 8 of Cycles 1 and 2, Day 1 of Cycles 3 to 16. | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. |
| Percentage of Participants With Objective Response - Arm B | Baseline up to 18 months. | Percentage of participants with objective response based on the assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm) and no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease and no new lesions. |
| Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion. | An adverse event (AE) was any untoward medical occurrence in a clinical investigation participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. Treatment Emergent AEs were those occurred for the first time after the start of study treatment and within 28 days after final dose of study treatment and was not seen prior to the start of treatment, or those were seen prior to the start of study treatment but increased in Common Terminology Criteria for Adverse Events (CTCAE) grade after the start of study treatment and within 28 days after final dose of study treatment. AEs were graded by the investigator according to the CTCAE version 4.03 : Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE. |
Countries
Canada, Italy, Spain, United Kingdom, United States
Participant flow
Recruitment details
Arm A included 5 sub-arms: Arms A1, A2, A3, A4, A5 Arm B included 8 sub-arms: Arms B1, B2, B3, B4, B5, B6, B7, B8 Arm C included 5 sub-arms: Arms C1, C1h, C2, C3, C4 Arm B Expansion included 2 sub-arms: Arms 1, 2
Pre-assignment details
A total of 110 subjets were enrolled in this study and 3 of them didn't received any study treatment.
Participants by arm
| Arm | Count |
|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel Participants with castrate resistant prostate cancer (CRPC), advanced breast cancer (ABC), or non-small cell lung cancer (NSCLC) that were candidates to treatment with a docetaxel-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 90 mg once on Day -7 and Cycle 1 Day 2, and docetaxel 75 mg/m2 1-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received docetaxel 75 mg/m2 1-hour IV infusion once followed by PF-05212384 90 mg once. The maximum duration of PF-05212384 treatment was 505 days and the maximum duration of docetaxel treatment was 445 days. | 4 |
| Arm A2: 110 mg PF-05212384 + Docetaxel Participants with CRPC, ABC, or NSCLC that were candidates to treatment with a docetaxel-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 110 mg once on Day -7 and Cycle 1 Day 2, and docetaxel 75 mg/m2 1-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received docetaxel 75 mg/m2 1-hour IV infusion once followed by PF-05212384 110 mg once. The maximum duration of PF-05212384 treatment was 505 days and the maximum duration of docetaxel treatment was 445 days. | 5 |
| Arm A3: 130 mg PF-05212384 + Docetaxel Participants with CRPC, ABC, or NSCLC that were candidates to treatment with a docetaxel-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 130 mg once on Day -7 and Cycle 1 Day 2, and docetaxel 75 mg/m2 1-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received docetaxel 75 mg/m2 1-hour IV infusion once followed by PF-05212384 130 mg once. The maximum duration of PF-05212384 treatment was 505 days and the maximum duration of docetaxel treatment was 445 days. | 3 |
| Arm A4: 150 mg PF-05212384 + Docetaxel Participants with CRPC, ABC, or NSCLC that were candidates to treatment with a docetaxel-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 150 mg once on Day -7 and Cycle 1 Day 2, and docetaxel 75 mg/m2 1-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received docetaxel 75 mg/m2 1-hour IV infusion once followed by PF-05212384 150 mg once. The maximum duration of PF-05212384 treatment was 505 days and the maximum duration of docetaxel treatment was 445 days. | 3 |
| Arm A5: 180 mg PF-05212384 + Docetaxel Participants with CRPC, ABC, or NSCLC that were candidates to treatment with a docetaxel-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 180 mg once on Day -7 and Cycle 1 Day 2, and docetaxel 75 mg/m2 1-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received docetaxel 75 mg/m2 1-hour IV infusion once followed by PF-05212384 180 mg once. The maximum duration of PF-05212384 treatment was 505 days and the maximum duration of docetaxel treatment was 445 days. | 5 |
| Arm B1: 90 mg PF-05212384 + Cisplatin Participants with urothelial transitional cell cancer (TCC), triple negative breast cancer (TNBC), NSCLC or ovarian cancer (OC) that were candidates to treatment with a cisplatin-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 90 mg once on Day -7 and Cycle 1 Day 2, and cisplatin 75 mg/m2 2-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received cisplatin 75 mg/m2 2-hour IV infusion once followed by PF-05212384 90 mg once. The maximum duration of PF-05212384 treatment was 414 days and the maximum duration of cisplatin treatment was 157 days. | 4 |
| Arm B2: 110 mg PF-05212384 + Cisplatin Participants with TCC, TNBC, NSCLC or OC that were candidates to treatment with a cisplatin-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 110 mg once on Day -7 and Cycle 1 Day 2, and cisplatin 75 mg/m2 2-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received cisplatin 75 mg/m2 2-hour IV infusion once followed by PF-05212384 110 mg once. The maximum duration of PF-05212384 treatment was 414 days and the maximum duration of cisplatin treatment was 157 days. | 3 |
| Arm B3: 130 mg PF-05212384 + Cisplatin Participants with TCC, TNBC, NSCLC or OC that were candidates to treatment with a cisplatin-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 130 mg once on Day -7 and Cycle 1 Day 2, and cisplatin 75 mg/m2 2-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received cisplatin 75 mg/m2 2-hour IV infusion once followed by PF-05212384 130 mg once. The maximum duration of PF-05212384 treatment was 414 days and the maximum duration of cisplatin treatment was 157 days. | 3 |
| Arm B4: 150 mg PF-05212384 + Cisplatin Participants with TCC, TNBC, NSCLC or OC that were candidates to treatment with a cisplatin-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 150 mg once on Day -7 and Cycle 1 Day 2, and cisplatin 75 mg/m2 2-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received cisplatin 75 mg/m2 2-hour IV infusion once followed by PF-05212384 150 mg once. The maximum duration of PF-05212384 treatment was 414 days and the maximum duration of cisplatin treatment was 157 days. | 3 |
| Arm B5: 180 mg PF-05212384 + Cisplatin Participants with TCC, TNBC, NSCLC or OC that were candidates to treatment with a cisplatin-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 180 mg once on Day -7 and Cycle 1 Day 2, and cisplatin 75 mg/m2 2-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received cisplatin 75 mg/m2 2-hour IV infusion once followed by PF-05212384 180 mg once. The maximum duration of PF-05212384 treatment was 414 days and the maximum duration of cisplatin treatment was 157 days. | 3 |
| Arm B6: 215 mg PF-05212384 + Cisplatin Participants with TCC, TNBC, NSCLC or OC that were candidates to treatment with a cisplatin-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 215 mg once on Day -7 and Cycle 1 Day 2, and cisplatin 75 mg/m2 2-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received cisplatin 75 mg/m2 2-hour IV infusion once followed by PF-05212384 215 mg once. The maximum duration of PF-05212384 treatment was 414 days and the maximum duration of cisplatin treatment was 157 days. | 10 |
| Arm B7: 260 mg PF-05212384 + Cisplatin Participants with TCC, TNBC, NSCLC or OC that were candidates to treatment with a cisplatin-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 260 mg once on Day -7 and Cycle 1 Day 2, and cisplatin 75 mg/m2 2-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received cisplatin 75 mg/m2 2-hour IV infusion once followed by PF-05212384 260 mg once. The maximum duration of PF-05212384 treatment was 414 days and the maximum duration of cisplatin treatment was 157 days. | 5 |
| Arm B8: 310 mg PF-05212384 + Cisplatin Participants with TCC, TNBC, NSCLC or OC that were candidates to treatment with a cisplatin-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 310 mg once on Day -7 and Cycle 1 Day 2, and cisplatin 75 mg/m2 2-hour IV infusion once on Cycle 1 Day 1. On Day 1 for Cycles 2 and beyond, participants received cisplatin 75 mg/m2 2-hour IV infusion once followed by PF-05212384 310 mg once. The maximum duration of PF-05212384 treatment was 414 days and the maximum duration of cisplatin treatment was 157 days. | 2 |
| Arm C1: 90 mg PF-052123 84 + 30 mg Dacomitinib Participants with Her2+ breast cancer (BC) refractory to prior herceptin or lapatinib, Her2+ esophago gastric cancer, head and neck squamous cell cancer (HNSCC), or NSCLC that were candidates to treatment with a dacomitinib-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 90 mg once on Day -14 and dacomitinib 30 mg orally once on Day -7. On Cycle 1 Day 1, participants received dacomitinib 30 mg orally once. On Cycle 1 Day 2, participants received treatment with dacomitinib 30 mg orally once followed by PF-05212384 90 mg once. On Day 1 for Cycles 2 and beyond, participants received dacomitinib 30 mg orally once followed by PF-05212384 90 mg once. The maximum duration of PF-05212384 treatment was 842 days and the maximum duration of dacomitinib treatment was 841 days. | 15 |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib Participants with BC refractory to prior herceptin or lapatinib, Her2+ esophago gastric cancer, HNSCC, or NSCLC that were candidates to treatment with a dacomitinib-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 90 mg once on Day -14 and dacomitinib 45 mg orally once on Day -7. On Cycle 1 Day 1, participants received dacomitinib 45 mg orally once. On Cycle 1 Day 2, participants received treatment with dacomitinib 45 mg orally once followed by PF-05212384 90 mg once. On Day 1 for Cycles 2 and beyond, participants received dacomitinib 45 mg orally once followed by PF-05212384 90 mg once. The maximum duration of PF-05212384 treatment was 842 days and the maximum duration of dacomitinib treatment was 841 days. | 4 |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib Participants with BC refractory to prior herceptin or lapatinib, Her2+ esophago gastric cancer, HNSCC, or NSCLC that were candidates to treatment with a dacomitinib-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 110 mg once on Day -14 and dacomitinib 30 mg orally once on Day -7. On Cycle 1 Day 1, participants received dacomitinib 30 mg orally once. On Cycle 1 Day 2, participants received treatment with dacomitinib 30 mg orally once followed by PF-05212384 110 mg once. On Day 1 for Cycles 2 and beyond, participants received dacomitinib 30 mg orally once followed by PF-05212384 110 mg once. The maximum duration of PF-05212384 treatment was 842 days and the maximum duration of dacomitinib treatment was 841 days. | 7 |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib Participants with BC refractory to prior herceptin or lapatinib, Her2+ esophago gastric cancer, HNSCC, or NSCLC that were candidates to treatment with a dacomitinib-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 130 mg once on Day -14 and dacomitinib 30 mg orally once on Day -7. On Cycle 1 Day 1, participants received dacomitinib 30 mg orally once. On Cycle 1 Day 2, participants received treatment with dacomitinib 30 mg orally once followed by PF-05212384 130 mg once. On Day 1 for Cycles 2 and beyond, participants received dacomitinib 30 mg orally once followed by PF-05212384 130 mg once. The maximum duration of PF-05212384 treatment was 842 days and the maximum duration of dacomitinib treatment was 841 days. | 3 |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib Participants with BC refractory to prior herceptin or lapatinib, Her2+ esophago gastric cancer, HNSCC, or NSCLC that were candidates to treatment with a dacomitinib-based combination. Each treatment cycle was defined as 21 days. Participants received intravenous infusion of PF-05212384 150 mg once on Day -14 and dacomitinib 30 mg orally once on Day -7. On Cycle 1 Day 1, participants received dacomitinib 30 mg orally once. On Cycle 1 Day 2, participants received treatment with dacomitinib 30 mg orally once followed by PF-05212384 150 mg once. On Day 1 for Cycles 2 and beyond, participants received dacomitinib 30 mg orally once followed by PF-05212384 150 mg once. The maximum duration of PF-05212384 treatment was 842 days and the maximum duration of dacomitinib treatment was 841 days. | 3 |
| Arm 1: 1L Metastatic Participants with TNBC with no prior cytotoxic chemotherapy therapy in the metastatic setting received intravenous infusion of cisplatin 75 mg/m2 2-hour IV infusion followed by intravenous infusion of PF-05212384 180 mg. The maximum duration of PF-05212384 treatment was 728 days and the maximum duration of cisplatin treatment was 211 days. | 10 |
| Arm 2: 2L/3L Metastatic Participants with TNBC and one or two prior cytotoxic therapies in the metastatic setting received intravenous infusion of cisplatin 75 mg/m2 2-hour IV infusion followed by intravenous infusion of PF-05212384 180 mg. The maximum duration of PF-05212384 treatment was 728 days and the maximum duration of cisplatin treatment was 211 days. | 12 |
| Total | 107 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 | FG013 | FG014 | FG015 | FG016 | FG017 | FG018 | FG019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Death | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Lost to Follow-up | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 3 |
| Overall Study | Other | 1 | 1 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 4 | 0 | 1 | 1 | 0 | 1 | 1 |
| Overall Study | Participant refused further follow-up | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 1 | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Arm A1: 90 mg PF-05212384 + Docetaxel | Arm A2: 110 mg PF-05212384 + Docetaxel | Arm A3: 130 mg PF-05212384 + Docetaxel | Arm A4: 150 mg PF-05212384 + Docetaxel | Arm A5: 180 mg PF-05212384 + Docetaxel | Arm B1: 90 mg PF-05212384 + Cisplatin | Arm B2: 110 mg PF-05212384 + Cisplatin | Arm B3: 130 mg PF-05212384 + Cisplatin | Arm B4: 150 mg PF-05212384 + Cisplatin | Arm B5: 180 mg PF-05212384 + Cisplatin | Arm B6: 215 mg PF-05212384 + Cisplatin | Arm B7: 260 mg PF-05212384 + Cisplatin | Arm B8: 310 mg PF-05212384 + Cisplatin | Arm C1: 90 mg PF-052123 84 + 30 mg Dacomitinib | Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Arm 1: 1L Metastatic | Arm 2: 2L/3L Metastatic | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 62.3 years STANDARD_DEVIATION 4.7 | 62.0 years STANDARD_DEVIATION 10.9 | 61.7 years STANDARD_DEVIATION 7.6 | 58.3 years STANDARD_DEVIATION 15.9 | 63.6 years STANDARD_DEVIATION 8.1 | 57.3 years STANDARD_DEVIATION 9.1 | 51.7 years STANDARD_DEVIATION 13.6 | 54.7 years STANDARD_DEVIATION 15.9 | 54.0 years STANDARD_DEVIATION 9.6 | 55.7 years STANDARD_DEVIATION 8.5 | 54.6 years STANDARD_DEVIATION 11.1 | 58.2 years STANDARD_DEVIATION 13.7 | 59.5 years STANDARD_DEVIATION 13.4 | 53.4 years STANDARD_DEVIATION 14.1 | 54.3 years STANDARD_DEVIATION 22.1 | 55.4 years STANDARD_DEVIATION 8.8 | 49.7 years STANDARD_DEVIATION 6.4 | 56.3 years STANDARD_DEVIATION 12.4 | 52.4 years STANDARD_DEVIATION 13.6 | 54.8 years STANDARD_DEVIATION 11.6 | 55.5 years STANDARD_DEVIATION 10.7 |
| Race/Ethnicity, Customized Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 5 Participants |
| Race/Ethnicity, Customized Black | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 5 Participants |
| Race/Ethnicity, Customized White | 4 Participants | 5 Participants | 3 Participants | 3 Participants | 3 Participants | 4 Participants | 3 Participants | 2 Participants | 3 Participants | 3 Participants | 9 Participants | 4 Participants | 2 Participants | 14 Participants | 3 Participants | 7 Participants | 2 Participants | 3 Participants | 9 Participants | 11 Participants | 97 Participants |
| Sex: Female, Male Female | 2 Participants | 3 Participants | 1 Participants | 2 Participants | 2 Participants | 2 Participants | 2 Participants | 2 Participants | 2 Participants | 3 Participants | 10 Participants | 3 Participants | 2 Participants | 8 Participants | 4 Participants | 0 Participants | 2 Participants | 1 Participants | 10 Participants | 12 Participants | 73 Participants |
| Sex: Female, Male Male | 2 Participants | 2 Participants | 2 Participants | 1 Participants | 3 Participants | 2 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 7 Participants | 0 Participants | 7 Participants | 1 Participants | 2 Participants | 0 Participants | 0 Participants | 34 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk | EG014 affected / at risk | EG015 affected / at risk | EG016 affected / at risk | EG017 affected / at risk | EG018 affected / at risk | EG019 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 4 | 1 / 5 | 0 / 3 | 1 / 3 | 0 / 5 | 0 / 4 | 0 / 3 | 1 / 3 | 0 / 3 | 1 / 3 | 0 / 10 | 1 / 5 | 0 / 2 | 0 / 15 | 2 / 4 | 0 / 7 | 0 / 3 | 0 / 3 | 0 / 10 | 1 / 12 |
| other Total, other adverse events | 4 / 4 | 5 / 5 | 3 / 3 | 3 / 3 | 5 / 5 | 4 / 4 | 3 / 3 | 3 / 3 | 3 / 3 | 3 / 3 | 10 / 10 | 5 / 5 | 2 / 2 | 15 / 15 | 4 / 4 | 7 / 7 | 3 / 3 | 3 / 3 | 10 / 10 | 12 / 12 |
| serious Total, serious adverse events | 2 / 4 | 2 / 5 | 0 / 3 | 1 / 3 | 1 / 5 | 1 / 4 | 1 / 3 | 1 / 3 | 3 / 3 | 3 / 3 | 4 / 10 | 2 / 5 | 2 / 2 | 3 / 15 | 2 / 4 | 3 / 7 | 0 / 3 | 0 / 3 | 2 / 10 | 4 / 12 |
Outcome results
Primary
Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C
DLT was defined as any of the following adverse events (AEs) attributable to the combination: (1) hematologic: grade 4 neutropenia lasting \>7 days; febrile neutropenia; grade \>=3 neutropenia with infection; grade 3 thrombocytopenia with bleeding; grade 4 thrombocytopenia; (2) non-hematologic: grade \>=2 pneumonitis; grade\>=3 toxicities, except pneumonitis, and excluding those that had not been maximally treated; persistent, intolerable toxicities which resulted in the failure to deliver at least 3 of the 4 doses of PF-05212384 for Arms A and B or at least 3 of the 4 doses of PF-05212384 and 75% of dacomitinib for Arm C during the first cycle; the persistent, intolerable toxicities which result in delay of the start of the second cycle by more than 2 weeks relative to the scheduled start; in an asymptomatic participant, the grade 3 QTc prolongation persists after correction of any reversible causes.
Time frame: Up to 21 days
Population: The per protocol analysis set included all enrolled participants who received at least one dose of study medication and who did not receive less than 75% or more than 125% of the planned Cycle 1 dose of either study drug in the combination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 3 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 3 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 3 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 8 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 13 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 5 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | No DLT | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | With DLT | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C | Data missing | 0 Participants |
Primary
Percentage of Participants With Objective Response - Arm B Expansion
Percentage of participants with objective response based on the assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm) and no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease and no new lesions.
Time frame: Cycle 1 Day 1 up to 18 months
Population: The response analysis set included all participants who received at least one dose of study medication, had the disease under study, and who had an adequate baseline tumor assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm B Expansion | 40.0 Percentage of participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm B Expansion | 33.3 Percentage of participants |
Secondary
Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B)
AUCtau is defined as area under the concentration-time profile from time 0 to time tau.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 7 days prior to Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 14620 ng*hr/mL | Geometric Coefficient of Variation 75 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 12690 ng*hr/mL | Geometric Coefficient of Variation 58 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | NA ng*hr/mL | — |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 18920 ng*hr/mL | Geometric Coefficient of Variation 77 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | NA ng*hr/mL | — |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 38850 ng*hr/mL | Geometric Coefficient of Variation 71 |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 27480 ng*hr/mL | Geometric Coefficient of Variation 46 |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | NA ng*hr/mL | — |
Secondary
Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion)
AUCtau is defined as area under the concentration-time profile from time 0 to time tau.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 25250 ng*hr/mL | Geometric Coefficient of Variation 49 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 31160 ng*hr/mL | Geometric Coefficient of Variation 27 |
Secondary
Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C)
AUCtau is defined as area under the concentration-time profile from time 0 to time tau.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | 10870 ng*hr/mL | Geometric Coefficient of Variation 36 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | NA ng*hr/mL | — |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | 9977 ng*hr/mL | Geometric Coefficient of Variation 22 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | 15910 ng*hr/mL | Geometric Coefficient of Variation 45 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | NA ng*hr/mL | — |
Secondary
Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A)
AUCtau is defined as area under the concentration-time profile from time 0 to time tau.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who have sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 10420 ng*hr/mL | Geometric Coefficient of Variation 44 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 15110 ng*hr/mL | Geometric Coefficient of Variation 22 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 15520 ng*hr/mL | Geometric Coefficient of Variation 26 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 14540 ng*hr/mL | Geometric Coefficient of Variation 56 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 15890 ng*hr/mL | Geometric Coefficient of Variation 27 |
Secondary
Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C)
AUCtau is defined as area under the concentration-time profile from time 0 to time tau.
Time frame: Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 818.8 ng*hr/mL | Geometric Coefficient of Variation 34 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 1604 ng*hr/mL | Geometric Coefficient of Variation 36 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 697.0 ng*hr/mL | Geometric Coefficient of Variation 62 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 1040 ng*hr/mL | Geometric Coefficient of Variation 34 |
Secondary
Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C)
AUCtau is defined as area under the concentration-time profile from time 0 to time tau.
Time frame: Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | 1069 ng*hr/mL | Geometric Coefficient of Variation 38 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | NA ng*hr/mL | — |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | 703.8 ng*hr/mL | Geometric Coefficient of Variation 100 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | NA ng*hr/mL | — |
Secondary
Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion)
AUCtau is defined as area under the concentration-time profile from time 0 to time tau.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 20180 ng*hr/mL | Geometric Coefficient of Variation 42 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Concentration-time Profile From Time 0 to Time Tau (AUCtau) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 24480 ng*hr/mL | Geometric Coefficient of Variation 22 |
Secondary
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B)
AUClast is defined as area under the curve from time zero to last quantifiable concentration.
Time frame: Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 59390 ng*hr/mL | Geometric Coefficient of Variation 7 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 62990 ng*hr/mL | Geometric Coefficient of Variation 11 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | NA ng*hr/mL | — |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 56170 ng*hr/mL | Geometric Coefficient of Variation 22 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 52940 ng*hr/mL | Geometric Coefficient of Variation 10 |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 53470 ng*hr/mL | Geometric Coefficient of Variation 11 |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 47500 ng*hr/mL | Geometric Coefficient of Variation 18 |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | NA ng*hr/mL | — |
Secondary
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Docetaxel in Combination With PF-05212384 - Plasma Docetaxel (Arm A)
AUClast is defined as area under the curve from time zero to last quantifiable concentration.
Time frame: Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Docetaxel in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 2921 ng*hr/mL | Geometric Coefficient of Variation 60 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Docetaxel in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 2175 ng*hr/mL | Geometric Coefficient of Variation 26 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Docetaxel in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | NA ng*hr/mL | — |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Docetaxel in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 1415 ng*hr/mL | Geometric Coefficient of Variation 115 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Administration of Docetaxel in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 1383 ng*hr/mL | Geometric Coefficient of Variation 136 |
Secondary
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B)
AUClast is defined as area under the curve from time zero to last quantifiable concentration.
Time frame: Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 50210 ng*hr/mL | Geometric Coefficient of Variation 7 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 50860 ng*hr/mL | Geometric Coefficient of Variation 6 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 44240 ng*hr/mL | Geometric Coefficient of Variation 8 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 48870 ng*hr/mL | Geometric Coefficient of Variation 18 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 42910 ng*hr/mL | Geometric Coefficient of Variation 23 |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 46560 ng*hr/mL | Geometric Coefficient of Variation 13 |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 48350 ng*hr/mL | Geometric Coefficient of Variation 24 |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | NA ng*hr/mL | — |
Secondary
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A)
AUClast is defined as area under the curve from time zero to last quantifiable concentration.
Time frame: Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 1418 ng*hr/mL | Geometric Coefficient of Variation 88 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 2748 ng*hr/mL | Geometric Coefficient of Variation 27 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 2111 ng*hr/mL | Geometric Coefficient of Variation 11 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 1594 ng*hr/mL | Geometric Coefficient of Variation 64 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 1280 ng*hr/mL | Geometric Coefficient of Variation 63 |
Secondary
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C)
AUClast is defined as area under the curve from time zero to last quantifiable concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 7 days prior to Cycle 1 Day 1 for Arms A and B; pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 14 days prior to Cycle 1 Day 1 for Arm C.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | NA ng*hr/mL | — |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 12530 ng*hr/mL | Geometric Coefficient of Variation 26 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 15270 ng*hr/mL | Geometric Coefficient of Variation 21 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | NA ng*hr/mL | — |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 18710 ng*hr/mL | Geometric Coefficient of Variation 28 |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 6756 ng*hr/mL | Geometric Coefficient of Variation 65 |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 8937 ng*hr/mL | Geometric Coefficient of Variation 21 |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | NA ng*hr/mL | — |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 14370 ng*hr/mL | Geometric Coefficient of Variation 16 |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 17710 ng*hr/mL | Geometric Coefficient of Variation 14 |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 24540 ng*hr/mL | Geometric Coefficient of Variation 35 |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 24480 ng*hr/mL | Geometric Coefficient of Variation 30 |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | NA ng*hr/mL | — |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 9191 ng*hr/mL | Geometric Coefficient of Variation 32 |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 13360 ng*hr/mL | Geometric Coefficient of Variation 35 |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 10050 ng*hr/mL | Geometric Coefficient of Variation 26 |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 9493 ng*hr/mL | Geometric Coefficient of Variation 32 |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 10370 ng*hr/mL | Geometric Coefficient of Variation 23 |
Secondary
Clinical Benefit Response Rate - Arm B Expansion
Percent of participants with confirmed complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks on study according to Response Evaluation Criteria in Solid Tumors (RECIST). Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm) and no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease and no new lesions. SD was defined as not qualifying for CR, PR, Progressive Disease (PD).
Time frame: Baseline up to 18 months.
Population: The response analysis set included all participants who received at least one dose of study medication, had the disease under study, and who had an adequate baseline tumor assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Clinical Benefit Response Rate - Arm B Expansion | 60.0 Percentage of participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Clinical Benefit Response Rate - Arm B Expansion | 50.0 Percentage of participants |
Secondary
Duration of Response - Arm B Expansion
Duration of response was calculated from first date of partial response (PR) or complete response (CR) to the date of progression or death due to any cause. In the event of no progression or death, the last tumor assessment date without progression was used in this calculation.
Time frame: Baseline up to 18 months.
Population: The response analysis set included all participants who received at least one dose of study medication, had the disease under study, had an adequate baseline tumor assessment, and who with objective response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Duration of Response - Arm B Expansion | 6.9 month |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Duration of Response - Arm B Expansion | NA month |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 3867 ng/mL | Geometric Coefficient of Variation 16 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 4201 ng/mL | Geometric Coefficient of Variation 7 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 3205 ng/mL | Geometric Coefficient of Variation 17 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 4086 ng/mL | Geometric Coefficient of Variation 10 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 3130 ng/mL | Geometric Coefficient of Variation 17 |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 3665 ng/mL | Geometric Coefficient of Variation 23 |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 3211 ng/mL | Geometric Coefficient of Variation 19 |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | NA ng/mL | — |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 1840 ng/mL | Geometric Coefficient of Variation 95 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 695.9 ng/mL | Geometric Coefficient of Variation 253 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 2457 ng/mL | Geometric Coefficient of Variation 18 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 1424 ng/mL | Geometric Coefficient of Variation 126 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 1300 ng/mL | Geometric Coefficient of Variation 238 |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 10670 ng/mL | Geometric Coefficient of Variation 114 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 7830 ng/mL | Geometric Coefficient of Variation 104 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 6273 ng/mL | Geometric Coefficient of Variation 102 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 9619 ng/mL | Geometric Coefficient of Variation 57 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | NA ng/mL | — |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 18730 ng/mL | Geometric Coefficient of Variation 24 |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 15000 ng/mL | Geometric Coefficient of Variation 19 |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | NA ng/mL | — |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 9027 ng/mL | Geometric Coefficient of Variation 52 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 14670 ng/mL | Geometric Coefficient of Variation 32 |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | 6739 ng/mL | Geometric Coefficient of Variation 50 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | NA ng/mL | — |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | 6328 ng/mL | Geometric Coefficient of Variation 31 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | 8547 ng/mL | Geometric Coefficient of Variation 48 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | NA ng/mL | — |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 8032 ng/mL | Geometric Coefficient of Variation 36 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 8095 ng/mL | Geometric Coefficient of Variation 33 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 10380 ng/mL | Geometric Coefficient of Variation 26 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 11110 ng/mL | Geometric Coefficient of Variation 53 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 10860 ng/mL | Geometric Coefficient of Variation 33 |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 41.04 ng/mL | Geometric Coefficient of Variation 33 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 76.24 ng/mL | Geometric Coefficient of Variation 45 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 34.17 ng/mL | Geometric Coefficient of Variation 61 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 49.90 ng/mL | Geometric Coefficient of Variation 38 |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | 52.38 ng/mL | Geometric Coefficient of Variation 36 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | NA ng/mL | — |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | 33.64 ng/mL | Geometric Coefficient of Variation 94 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | 48.10 ng/mL | Geometric Coefficient of Variation 72 |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 3397 ng/mL | Geometric Coefficient of Variation 29 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 3950 ng/mL | Geometric Coefficient of Variation 1 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 3014 ng/mL | Geometric Coefficient of Variation 10 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 4041 ng/mL | Geometric Coefficient of Variation 14 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 3337 ng/mL | Geometric Coefficient of Variation 8 |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 3474 ng/mL | Geometric Coefficient of Variation 31 |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 3293 ng/mL | Geometric Coefficient of Variation 18 |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | NA ng/mL | — |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 946.7 ng/mL | Geometric Coefficient of Variation 116 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 2451 ng/mL | Geometric Coefficient of Variation 23 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 2528 ng/mL | Geometric Coefficient of Variation 19 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 1529 ng/mL | Geometric Coefficient of Variation 93 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 1058 ng/mL | Geometric Coefficient of Variation 161 |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 7 days prior to Cycle 1 Day 1 for Arms A and B; pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 14 days prior to Cycle 1 Day 1 for Arm C.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 6455 ng/mL | Geometric Coefficient of Variation 30 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 9539 ng/mL | Geometric Coefficient of Variation 24 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 12090 ng/mL | Geometric Coefficient of Variation 21 |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 7128 ng/mL | Geometric Coefficient of Variation 154 |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 12420 ng/mL | Geometric Coefficient of Variation 27 |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 4522 ng/mL | Geometric Coefficient of Variation 76 |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 7297 ng/mL | Geometric Coefficient of Variation 6 |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 7969 ng/mL | Geometric Coefficient of Variation 39 |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 9548 ng/mL | Geometric Coefficient of Variation 20 |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 13350 ng/mL | Geometric Coefficient of Variation 54 |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 15170 ng/mL | Geometric Coefficient of Variation 63 |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 11510 ng/mL | Geometric Coefficient of Variation 61 |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | NA ng/mL | — |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 6703 ng/mL | Geometric Coefficient of Variation 57 |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 8999 ng/mL | Geometric Coefficient of Variation 49 |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 6783 ng/mL | Geometric Coefficient of Variation 24 |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 4266 ng/mL | Geometric Coefficient of Variation 80 |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 8261 ng/mL | Geometric Coefficient of Variation 12 |
Secondary
Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion)
Cmax is defined as maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 11340 ng/mL | Geometric Coefficient of Variation 60 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Maximum Observed Plasma Concentration (Cmax) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 10690 ng/mL | Geometric Coefficient of Variation 44 |
Secondary
Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
Time frame: Baseline, Day 1 and Day 8 of Cycles 1 and 2, Day 1 of Cycles 3 to 16.
Population: All enrolled participants who started treatment on study drug and who completed a baseline assessment and at least one post baseline assessment.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 2 Day 1 | -11.46 Score on a scale | Standard Deviation 24.372 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 9 Day 1 | -4.16 Score on a scale | Standard Deviation 20.971 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 5 Day 1 | -21.67 Score on a scale | Standard Deviation 34.66 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 10 Day 1 | 5.55 Score on a scale | Standard Deviation 25.458 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 3 Day 1 | -10.42 Score on a scale | Standard Deviation 33.591 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 11 Day 1 | 0.01 Score on a scale | Standard Deviation 23.568 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 6 Day 1 | -11.67 Score on a scale | Standard Deviation 24.719 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 12 Day 1 | 8.34 Score on a scale | Standard Deviation 35.348 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 2 Day 8 | -14.28 Score on a scale | Standard Deviation 26.665 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 13 Day 1 | NA Score on a scale | — |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 7 Day 1 | -20.00 Score on a scale | Standard Deviation 26.743 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 14 Day 1 | NA Score on a scale | — |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 4 Day 1 | -14.58 Score on a scale | Standard Deviation 29.165 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 15 Day 1 | NA Score on a scale | — |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 8 Day 1 | -15.00 Score on a scale | Standard Deviation 18.063 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 16 Day 1 | NA Score on a scale | — |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 1 Day 8 | -16.67 Score on a scale | Standard Deviation 23.57 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 16 Day 1 | -8.33 Score on a scale | Standard Deviation 22.049 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 1 Day 8 | -9.17 Score on a scale | Standard Deviation 16.411 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 2 Day 1 | -1.52 Score on a scale | Standard Deviation 9.734 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 2 Day 8 | -7.14 Score on a scale | Standard Deviation 25.2 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 3 Day 1 | 1.85 Score on a scale | Standard Deviation 18.054 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 4 Day 1 | -7.41 Score on a scale | Standard Deviation 20.601 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 5 Day 1 | -5.21 Score on a scale | Standard Deviation 30.839 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 6 Day 1 | -8.33 Score on a scale | Standard Deviation 22.361 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 7 Day 1 | 0.00 Score on a scale | Standard Deviation 10.545 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 8 Day 1 | -8.33 Score on a scale | Standard Deviation 31.178 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 9 Day 1 | -4.16 Score on a scale | Standard Deviation 22.047 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 10 Day 1 | -4.16 Score on a scale | Standard Deviation 30.808 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 11 Day 1 | -6.25 Score on a scale | Standard Deviation 24.883 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 12 Day 1 | -8.34 Score on a scale | Standard Deviation 32.631 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 13 Day 1 | 0.00 Score on a scale | Standard Deviation 30.044 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 14 Day 1 | -5.56 Score on a scale | Standard Deviation 39.381 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Change From Baseline for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 15 Day 1 | -2.78 Score on a scale | Standard Deviation 29.264 |
Secondary
Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
Time frame: Baseline, Day 1 and Day 8 of Cycles 1 and 2, Day 1 of Cycles 3 to 16.
Population: All enrolled participants who started treatment on study drug and who completed a baseline assessment and at least one post baseline assessment.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Baseline | 64.58 Score on a scale | Standard Deviation 18.232 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 1 Day 8 | 50.00 Score on a scale | Standard Deviation 23.57 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 2 Day 1 | 53.12 Score on a scale | Standard Deviation 28.499 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 2 Day 8 | 50.00 Score on a scale | Standard Deviation 25.911 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 3 Day 1 | 56.25 Score on a scale | Standard Deviation 38.112 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 4 Day 1 | 45.84 Score on a scale | Standard Deviation 31.551 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 5 Day 1 | 45.00 Score on a scale | Standard Deviation 32.059 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 6 Day 1 | 55.00 Score on a scale | Standard Deviation 33.125 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 7 Day 1 | 46.67 Score on a scale | Standard Deviation 26.745 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 8 Day 1 | 51.67 Score on a scale | Standard Deviation 25.274 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 9 Day 1 | 56.25 Score on a scale | Standard Deviation 20.835 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 10 Day 1 | 66.67 Score on a scale | Standard Deviation 16.665 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 11 Day 1 | 54.17 Score on a scale | Standard Deviation 17.678 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 12 Day 1 | 62.50 Score on a scale | Standard Deviation 29.458 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 13 Day 1 | NA Score on a scale | — |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 14 Day 1 | NA Score on a scale | — |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 15 Day 1 | NA Score on a scale | — |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 16 Day 1 | NA Score on a scale | — |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 12 Day 1 | 52.08 Score on a scale | Standard Deviation 23.936 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Baseline | 58.33 Score on a scale | Standard Deviation 19.003 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 8 Day 1 | 44.44 Score on a scale | Standard Deviation 20.86 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 1 Day 8 | 50.00 Score on a scale | Standard Deviation 26.058 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 16 Day 1 | 55.56 Score on a scale | Standard Deviation 9.624 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 2 Day 1 | 56.82 Score on a scale | Standard Deviation 17.802 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 9 Day 1 | 56.25 Score on a scale | Standard Deviation 24.883 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 2 Day 8 | 52.38 Score on a scale | Standard Deviation 12.468 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 13 Day 1 | 63.89 Score on a scale | Standard Deviation 17.346 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 3 Day 1 | 57.41 Score on a scale | Standard Deviation 16.896 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 10 Day 1 | 56.25 Score on a scale | Standard Deviation 15.778 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 4 Day 1 | 48.15 Score on a scale | Standard Deviation 19.886 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 15 Day 1 | 61.11 Score on a scale | Standard Deviation 19.243 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 5 Day 1 | 51.04 Score on a scale | Standard Deviation 23.753 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 11 Day 1 | 54.17 Score on a scale | Standard Deviation 20.971 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 6 Day 1 | 51.39 Score on a scale | Standard Deviation 15.293 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 14 Day 1 | 58.33 Score on a scale | Standard Deviation 25 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Observed Score Values for European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) - Arm B Expansion | Cycle 7 Day 1 | 52.78 Score on a scale | Standard Deviation 20.185 |
Secondary
Mean Serum Biomarkers for Glucose - Baseline
A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This study employed metabolic biomarkers such as glucose as pharmacodynamics markers for dual PI3K/mTOR inhibition.
Time frame: Baseline
Population: The serum pharmacodynamic analysis set was defined as all enrolled participants who started treatment and had a baseline and at least one post baseline measurement.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of BC | 106.80 mg/dL | Standard Deviation 18.82 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of NSCLC | 99.56 mg/dL | Standard Deviation 15.316 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of prostate cancer | 124.51 mg/dL | Standard Deviation 20.624 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of NSCLC | 100.97 mg/dL | Standard Deviation 9.154 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of OC | 102.71 mg/dL | Standard Deviation 15.29 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of TCC | 109.70 mg/dL | Standard Deviation 18.335 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of TNBC | 95.66 mg/dL | Standard Deviation 10.659 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of BC | 95.07 mg/dL | Standard Deviation 12.019 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of NSCLC | 97.00 mg/dL | Standard Deviation 10.1 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of oesophageal carcinoma | 103.54 mg/dL | Standard Deviation 14.97 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - Baseline | In population of head and neck cancer | 90.68 mg/dL | Standard Deviation 14.422 |
Secondary
Mean Serum Biomarkers for Glucose - End of Treatment
A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This studies employed metabolic biomarkers such as glucose as pharmacodynamics markers for dual PI3K/mTOR inhibition.
Time frame: End of treatment. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion.
Population: The serum pharmacodynamic analysis set was defined as all enrolled participants who started treatment and had a baseline and at least one post baseline measurement.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of BC | 120.00 mg/dL | Standard Deviation 37.242 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of NSCLC | 96.13 mg/dL | Standard Deviation 10.5 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of prostate cancer | 136.91 mg/dL | Standard Deviation 59.555 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of NSCLC | 108.11 mg/dL | Standard Deviation 10.698 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of OC | 143.26 mg/dL | Standard Deviation 34.404 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of TCC | 100.71 mg/dL | Standard Deviation 24.112 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of TNBC | 108.29 mg/dL | Standard Deviation 36.21 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of BC | 99.84 mg/dL | Standard Deviation 12.82 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of NSCLC | 97.50 mg/dL | Standard Deviation 17.046 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of oesophageal carcinoma | 1.14 mg/dL | Standard Deviation 0.21 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Glucose - End of Treatment | In population of head and neck cancer | 90.19 mg/dL | Standard Deviation 15.367 |
Secondary
Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline
A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This studies employed metabolic biomarkers such as hemoglobin A1c (HbA1c) as pharmacodynamics markers for dual PI3K/mTOR inhibition.
Time frame: Baseline
Population: The serum pharmacodynamic analysis set was defined as all enrolled participants who started treatment and had a baseline and at least one post baseline measurement.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of BC | 7.92 Percentage of HbA1c | Standard Deviation 0.115 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of NSCLC | 7.27 Percentage of HbA1c | Standard Deviation 1.074 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of prostate cancer | 8.03 Percentage of HbA1c | Standard Deviation 0.465 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of NSCLC | 6.65 Percentage of HbA1c | Standard Deviation 0.931 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of OC | 7.70 Percentage of HbA1c | Standard Deviation 0.354 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of TCC | 7.65 Percentage of HbA1c | Standard Deviation 0.696 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of TNBC | 7.18 Percentage of HbA1c | Standard Deviation 1.195 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of BC | 7.00 Percentage of HbA1c | Standard Deviation 1.742 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of NSCLC | 5.13 Percentage of HbA1c | Standard Deviation 0.065 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of oesophageal carcinoma | 7.00 Percentage of HbA1c | Standard Deviation 1.065 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - Baseline | In population of head and neck cancer | 7.50 Percentage of HbA1c | Standard Deviation 1.107 |
Secondary
Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment
A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This studies employed metabolic biomarkers such as hemoglobin A1c (HbA1c) as pharmacodynamics markers for dual PI3K/mTOR inhibition.
Time frame: End of treatment. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion.
Population: The serum pharmacodynamics analysis set was defined as all enrolled participants who started treatment and had a baseline and at least one post baseline measurement.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of BC | NA Percentage of HbA1c | — |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of NSCLC | 7.70 Percentage of HbA1c | Standard Deviation 1.087 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of prostate cancer | 8.42 Percentage of HbA1c | Standard Deviation 1.332 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of NSCLC | 6.74 Percentage of HbA1c | Standard Deviation 1.572 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of OC | 25.10 Percentage of HbA1c | Standard Deviation 22.698 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of TCC | 7.72 Percentage of HbA1c | Standard Deviation 0.551 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of TNBC | 7.72 Percentage of HbA1c | Standard Deviation 1.408 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of BC | 8.39 Percentage of HbA1c | Standard Deviation 1.05 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of NSCLC | NA Percentage of HbA1c | — |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of oesophageal carcinoma | 7.61 Percentage of HbA1c | Standard Deviation 1.404 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Hemoglobin A1c (HbA1c) - End of Treatment | In population of head and neck cancer | 7.72 Percentage of HbA1c | Standard Deviation 1.012 |
Secondary
Mean Serum Biomarkers for Insulin - Baseline
A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This studies employed metabolic biomarkers such as insulin as pharmacodynamics markers for dual PI3K/mTOR inhibition.
Time frame: Baseline
Population: The serum pharmacodynamic analysis set was defined as all enrolled participants who started treatment and had a baseline and at least one post baseline measurement.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of BC | 10.93 microunits/mL | Standard Deviation 3.942 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of NSCLC | 28.61 microunits/mL | Standard Deviation 56.678 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of prostate cancer | 12.65 microunits/mL | Standard Deviation 13.268 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of NSCLC | 710.50 microunits/mL | Standard Deviation 1346.142 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of OC | 12.50 microunits/mL | Standard Deviation 1.98 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of TCC | 20.68 microunits/mL | Standard Deviation 3.446 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of TNBC | 81.16 microunits/mL | Standard Deviation 204.586 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of BC | 155.14 microunits/mL | Standard Deviation 212.916 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of NSCLC | 11.53 microunits/mL | Standard Deviation 4.279 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of oesophageal carcinoma | 338.98 microunits/mL | Standard Deviation 441.323 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - Baseline | In population of head and neck cancer | 101.31 microunits/mL | Standard Deviation 187.285 |
Secondary
Mean Serum Biomarkers for Insulin - End of Treatment
A phosphatidylinositol 3 kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor should disrupt the cellular uptake and metabolism of glucose. This studies employed metabolic biomarkers such as insulin as pharmacodynamics markers for dual PI3K/mTOR inhibition.
Time frame: End of treatment. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion.
Population: The serum pharmacodynamic analysis set was defined as all enrolled participants who started treatment and had a baseline and at least one post baseline measurement.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of BC | 19.17 microunits/mL | Standard Deviation 8.578 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of prostate cancer | 13.73 microunits/mL | Standard Deviation 17.017 |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of NSCLC | 22.34 microunits/mL | Standard Deviation 20.913 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of OC | 80.30 microunits/mL | Standard Deviation 81.459 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of NSCLC | 832.87 microunits/mL | Standard Deviation 806.616 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of TNBC | 56.69 microunits/mL | Standard Deviation 120.565 |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of TCC | 41.65 microunits/mL | Standard Deviation 8.505 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of oesophageal carcinoma | 436.94 microunits/mL | Standard Deviation 612.108 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of NSCLC | 18.26 microunits/mL | Standard Deviation 10.559 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of head and neck cancer | 289.32 microunits/mL | Standard Deviation 606.589 |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Mean Serum Biomarkers for Insulin - End of Treatment | In population of BC | 318.62 microunits/mL | Standard Deviation 365.374 |
Secondary
Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry
Laboratory abnormalities were graded per NCI CTCAE version 4.03 (Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Following parameters were analyzed for laboratory examination: alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), total bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia.
Time frame: From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion.
Population: The safety analysis set included all enrolled participants who received at least one dose of study medication.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 3 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 3 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 3 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 3 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 3 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 3 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 3 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 5 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 2 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 5 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 5 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 5 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 3 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 3 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 5 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 3 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 3 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 3 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 3 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 3 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 3 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 3 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 3 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 3 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 3 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 3 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 9 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 8 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 10 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 3 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 8 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 9 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 8 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 5 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 10 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 5 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 4 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 3 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 3 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 5 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 9 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 5 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 6 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 4 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 9 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 3 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 6 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 4 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 10 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 4 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 5 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 4 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 5 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 4 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 5 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 5 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 5 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 5 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 3 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 5 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 3 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 2 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 9 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 13 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 11 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 12 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 8 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 2 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 12 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 15 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 15 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 13 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 9 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 10 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 15 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 10 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 3 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 3 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 5 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 14 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 2 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 9 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 13 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 4 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 5 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 3 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 3 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 3 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 3 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 3 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 3 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 3 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 6 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 7 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 4 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 6 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 4 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 7 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 6 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 5 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 5 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 6 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 5 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 7 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 5 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 7 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 7 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 6 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 7 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 10 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 5 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 2 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 5 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 9 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 8 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 4 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 10 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 6 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 10 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 10 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 8 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 5 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 4 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 5 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 4 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 2 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 4 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 10 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 5 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 9 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 4 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 10 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 7 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 6 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 0 | 11 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 1 | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 3 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 3 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 2 | 4 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 0 | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 1 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 1 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 2 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 1 | 6 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 0 | 7 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 0 | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 1 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 0 | 10 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 3 | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 3 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 0 | 7 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 1 | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 0 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 2 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 2 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 1 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 1 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | ALT | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 0 | 12 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 0 | 10 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 0 | 4 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 2 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyponatremia | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 0 | 12 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 1 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 1 | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 1 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypernatremia | Grade 0 | 12 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 0 | 8 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperkalemia | Grade 1 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 0 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 2 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 1 | 6 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoglycemia | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypermagnesemia | Grade 0 | 11 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Alkaline phosphatase | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypercalcemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 2 | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | AST | Grade 0 | 6 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypokalemia | Grade 3 | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 1 | 7 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hyperglycemia | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 2 | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Bilirubin (total) | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Creatinine | Grade 1 | 4 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypomagnesemia | Grade 1 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 1 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypophosphatemia | Grade 0 | 8 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypoalbuminemia | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Chemistry | Hypocalcemia | Grade 3 | 0 Participants |
Secondary
Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation
Laboratory abnormalities were graded per NCI CTCAE version 4.03 (Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Following parameters were analyzed for laboratory examination: partial thromboplastin time and prothrombin time international normalized ratio(INR).
Time frame: From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion.
Population: The safety analysis set included all enrolled participants who received at least one dose of study medication.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 3 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 4 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 3 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 3 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 9 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 9 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 5 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 5 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 7 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 13 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 4 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 6 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 2 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 8 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 9 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 2 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 1 | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 1 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Partial thromboplastin time | Grade 0 | 10 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Coagulation | Prothrombin time INR | Grade 0 | 10 Participants |
Secondary
Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology
Laboratory abnormalities were graded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Following parameters were analyzed for laboratory examination: anemia,hemoglobin increased, platelets, white blood cells, absolute neutrophils,lymphocyte count increased, lymphopenia.
Time frame: From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion.
Population: The safety analysis set included all enrolled participants who received at least one dose of study medication.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 3 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 5 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 5 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 2 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 3 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 2 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 2 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 5 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 3 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 3 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 3 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 3 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 3 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 3 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 3 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 6 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 9 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 4 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 4 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 6 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 5 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 10 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 5 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 5 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 4 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 14 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 5 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 15 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 7 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 15 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 5 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 15 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 10 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 3 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 7 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 7 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 4 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 5 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 6 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 7 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 6 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 3 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 3 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 3 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 9 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 4 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 2 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 4 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 2 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 3 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 7 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 3 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 2 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 2 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 10 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 3 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 6 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 2 | 4 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 0 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 1 | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 3 | 4 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 2 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 1 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 2 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 1 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 3 | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 2 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 1 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 3 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 3 | 4 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 0 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 1 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 0 | 12 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 2 | 8 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 1 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | White blood cells | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Anemia | Grade 0 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphopenia | Grade 0 | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 1 | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 4 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Hemoglobin increased | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Platelets | Grade 0 | 7 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Absolute neutrophils | Grade 2 | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Hematology | Lymphocyte count increased | Grade 0 | 12 Participants |
Secondary
Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis
Laboratory abnormalities were graded per NCI CTCAE version 4.03 (Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Following parameter was analyzed for laboratory examination: urine protein.
Time frame: From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion.
Population: The safety analysis set included all enrolled participants who received at least one dose of study medication.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 3 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 3 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 1 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 3 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 8 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 5 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 3 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 3 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 8 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 3 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 0 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 4 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 1 | 7 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Laboratory Abnormalities by Severity (All Cycles) - Urinalysis | Grade 2 | 0 Participants |
Secondary
Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria
QT interval corrected using Fridericia's formula (QTcF) and Bazette's formula (QTcB): QT interval (time corresponding to the beginning of depolarization to re-polarization of the ventricles) divided by cube root of RR interval. Maximum QTcF was categorized as less than (\<) 450 milliseconds (msec), 450 msec to 480 msec, 480 msec to 500 msec, and more than (\>) 500 msec.
Time frame: Baseline, Cycle 1 Day 1 (for Arm B Expansion), Cycle 1 Day 2 (for Arms A, B and C), Cycle 2 Day 1 (for Arms A, B and C), Day 1 for each cycle (Cycles 3-36, for Arms B Expansion and C) and end of treatment (up to 2 years, for Arms B Expansion and C).
Population: The QTc analysis set was defined as all enrolled participants who had at least one ECG assessment after receiving study drug or study drugs.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 3 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 2 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 5 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 3 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 3 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 3 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 3 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 3 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 3 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 10 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 3 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 7 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 4 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 11 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 14 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 3 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 4 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 5 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 5 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 8 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 4 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 450 <= Value <= 480 | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 450 <= Value <= 480 | 7 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | < 450 | 7 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | 480 < Value <=500 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcF interval (Fridericia's correction) (msec) | > 500 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | < 450 | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | > 500 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Corrected QT (QTc) Interval Meeting Pre-defined Criteria | Maximum QTcB interval (Bazett's correction) (msec) | 480 < Value <=500 | 2 Participants |
Secondary
Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized.
Time frame: Baseline, Cycle 1 Day 1 (for Arm B Expansion), Cycle 1 Day 2 (for Arms A, B and C), Cycle 2 Day 1 (for Arms A, B and C), Day 1 for each cycle (Cycles 3-36, for Arms B Expansion and C) and end of treatment (up to 2 years, for Arms B Expansion and C).
Population: The QTc analysis set was defined as all enrolled participants who had at least one ECG assessment after receiving study drug or study drugs.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 4 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 5 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 5 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 3 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 4 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 4 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 4 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 3 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 3 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 3 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 10 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 10 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 11 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 10 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 5 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 6 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 3 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 9 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 9 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change > 60 | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change > 60 | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | 30 < Change <= 60 | 4 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | 30 < Change <= 60 | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcB interval (Bazett's correction) increase from baseline (msec) | Change <= 30 | 7 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Maximum Increase From Baseline in Corrected QT (QTc) Interval | Maximum QTcF interval (Fridericia's correction) increase from baseline (msec) | Change <= 30 | 9 Participants |
Secondary
Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. Treatment Emergent AEs were those occurred for the first time after the start of study treatment and within 28 days after final dose of study treatment and was not seen prior to the start of treatment, or those were seen prior to the start of study treatment but increased in Common Terminology Criteria for Adverse Events (CTCAE) grade after the start of study treatment and within 28 days after final dose of study treatment. AEs were graded by the investigator according to the CTCAE version 4.03 : Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE.
Time frame: From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion.
Population: The safety analysis set included all enrolled participants who received at least one dose of study medication.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 2 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 9 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 2 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 5 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 4 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 4 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 3 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 8 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 4 AEs | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 2 AEs | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Treatment-Emergent Adverse Events (All Causality) - Arms A, B, C and B Expansion | Grade 3 AEs | 7 Participants |
Secondary
Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. Treatment Emergent AEs were those occurred for the first time after the start of study treatment and within 28 days after final dose of study treatment and was not seen prior to the start of treatment, or those were seen prior to the start of study treatment but increased in Common Terminology Criteria for Adverse Events (CTCAE) grade after the start of study treatment and within 28 days after final dose of study treatment. AEs were graded by the investigator according to the CTCAE version 4.03 : Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE.
Time frame: From the first dose of study drugs up to 28 days after the last dose of study drugs. Maximum duration between first and last dose: 505 days for Arm A, 414 days for Arm B, 842 days for Arm C, 728 days for Arm B Expansion.
Population: The safety analysis set included all enrolled participants who received at least one dose of study medication.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 2 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 3 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 5 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 9 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 1 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 3 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 4 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 6 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 4 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 3 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 4 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 3 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 1 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 2 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 6 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 4 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 4 AEs | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 1 AEs | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 5 AEs | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 2 AEs | 4 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) - Arms A, B, C and B Expansion | Grade 3 AEs | 6 Participants |
Secondary
Number of Participants With Vital Signs Data Meeting Pre-defined Criteria
Blood pressure (BP), including systolic BP (SBP) and diastolic BP (DBP), and pulse rate were recorded in sitting position.
Time frame: From baseline up to follow up (at least 28 days and no more than 35 days after discontinuation of treatment). Maximum duration between first and last dose: 842 days.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 2 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 1 Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 2 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 0 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 1 Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 2 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 3 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 1 Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 1 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 0 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 1 Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 2 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 1 Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 1 Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 1 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 2 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 1 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 2 Participants |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 3 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 4 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 8 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 3 Participants |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 1 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 2 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 2 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 1 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 0 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 3 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 2 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 5 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 4 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 1 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 4 Participants |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 1 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 0 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 1 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 3 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 2 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 4 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 0 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 2 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 1 Participants |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 0 Participants |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 3 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 7 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 1 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 6 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 4 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 6 Participants |
| Arm 1: 1L Metastasic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=40 mmHg | 1 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=20 mmHg | 4 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=30 mmHg | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=20 mmHg | 3 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP>=100 mmHg | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate>120 bpm | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP>=160 mmHg | 2 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting SBP<=100 mmHg | 6 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting DBP>=10 mmHg | 5 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting DBP<=60 mmHg | 6 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Max increase from baseline in sitting SBP>=60 mmHg | 0 Participants |
| Arm 2: 2L/3L Metastatic | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Sitting heart rate<50 bpm | 0 Participants |
Secondary
Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C
Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP.
Time frame: Baseline
Population: The molecular profiling tumor analysis set was defined as all enrolled participants who start treatment and had baseline archived tumor biopsy formalin fixed paraffin embedded (FFPE) sample (or fresh FFPE if archived was not available) successfully analyzed for at least one of the selected biomarkers.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | BRAF - BRAF mutaion status (mutation not detected) | 33.3 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | BRAF - V600E (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | BRAF - V600E (mutation not detected) | 66.7 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ALA (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ALA (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ARG (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12CYS (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12CYS (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12SER (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12VAL (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12VAL (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY13ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12SER (mutation not detected) | 80.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ASP (mutation not detected) | 80.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | BRAF - BRAF mutaion status (mutation not detected) | 40.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY13ASP (mutation not detected) | 80.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | BRAF - V600E (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12CYS (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | BRAF - V600E (mutation not detected) | 40.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12VAL (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ALA (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12CYS (mutation not detected) | 80.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ALA (mutation not detected) | 80.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ARG (mutation not detected) | 80.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12VAL (mutation not detected) | 80.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Breast Cancer - Arms A and C | KRAS - GLY12ASP (mutation detected) | 0 Percentage of Participants |
Secondary
Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C
Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP.
Time frame: Baseline
Population: The molecular profiling tumor analysis set was defined as all enrolled participants who started treatment and had baseline archived tumor biopsy formalin fixed paraffin embedded (FFPE) sample (or fresh FFPE if archived was not available) successfully analyzed for at least one of the selected biomarkers.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | BRAF - BRAF mutaion status (mutation not detected) | 10.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | BRAF - V600E (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | BRAF - V600E (mutation not detected) | 90.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12ALA (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12ALA (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12ARG (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12CYS (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12CYS (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12SER (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12VAL (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY12VAL (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Head and Neck Cancer - Arm C | KRAS - GLY13ASP (mutation not detected) | 100.0 Percentage of Participants |
Secondary
Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C
Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP.
Time frame: Baseline
Population: The molecular profiling tumor analysis set was defined as all enrolled participants who start treatment and had baseline archived tumor biopsy formalin fixed paraffin embedded (FFPE) sample (or fresh FFPE if archived was not available) successfully analyzed for at least one of the selected biomarkers.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ALA (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - BRAF mutaion status (mutation not detected) | 14.3 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - V600E (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - V600E (mutation not detected) | 85.7 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ALA (mutation not detected) | 85.7 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ARG (mutation not detected) | 85.7 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ASP (mutation detected) | 14.3 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ASP (mutation not detected) | 71.4 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12CYS (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12CYS (mutation not detected) | 85.7 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12SER (mutation not detected) | 85.7 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12VAL (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12VAL (mutation not detected) | 85.7 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY13ASP (mutation not detected) | 85.7 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY13ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - BRAF mutaion status (mutation not detected) | 80.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12VAL (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12VAL (mutation not detected) | 100.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - V600E (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12CYS (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - V600E (mutation not detected) | 20.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ASP (mutation detected) | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12SER (mutation not detected) | 100.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ALA (mutation detected) | 5 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ARG (mutation not detected) | 100.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12CYS (mutation not detected) | 100.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ALA (mutation not detected) | 100.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ALA (mutation not detected) | 100.0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ARG (mutation not detected) | 100.0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12VAL (mutation detected) | 0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ASP (mutation detected) | 0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY13ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12CYS (mutation detected) | 0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12VAL (mutation not detected) | 100.0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12CYS (mutation not detected) | 100.0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - BRAF mutaion status (mutation not detected) | 25.0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - V600E (mutation detected) | 0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | BRAF - V600E (mutation not detected) | 75.0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12ALA (mutation detected) | 0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY12SER (mutation not detected) | 100.0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Non-Small Cell Lung Cancer - Arms A, B and C | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
Secondary
Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C
Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP.
Time frame: Baseline
Population: The molecular profiling tumor analysis set was defined as all enrolled participants who started treatment and had baseline archived tumor biopsy formalin fixed paraffin embedded (FFPE) sample (or fresh FFPE if archived was not available) successfully analyzed for at least one of the selected biomarkers.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | BRAF - BRAF mutaion status (mutation not detected) | 42.9 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | BRAF - V600E (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | BRAF - V600E (mutation not detected) | 42.9 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12ALA (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12ALA (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12ARG (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12ASP (mutation detected) | 14.3 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12ASP (mutation not detected) | 85.7 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12CYS (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12CYS (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12SER (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12VAL (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY12VAL (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Oesophageal Carcinoma - Arm C | KRAS - GLY13ASP (mutation not detected) | 100.0 Percentage of Participants |
Secondary
Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B
Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation category was BRAF mutation status. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP.
Time frame: Baseline
Population: The molecular profiling tumor analysis set was defined as all enrolled participants who start treatment and had baseline archived tumor biopsy formalin fixed paraffin embedded (FFPE) sample (or fresh FFPE if archived was not available) successfully analyzed for at least one of the selected biomarkers.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | BRAF - BRAF mutaion status (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12ALA (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12ALA (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12ARG (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12CYS (mutation detected) | 50.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12CYS (mutation not detected) | 50.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12SER (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12VAL (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY12VAL (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Ovarian Cancer - Arm B | KRAS - GLY13ASP (mutation not detected) | 100.0 Percentage of Participants |
Secondary
Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A
Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP.
Time frame: Baseline
Population: The molecular profiling tumor analysis set was defined as all enrolled participants who start treatment and had baseline archived tumor biopsy formalin fixed paraffin embedded (FFPE) sample (or fresh FFPE if archived was not available) successfully analyzed for at least one of the selected biomarkers.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | BRAF - BRAF mutaion status (mutation not detected) | 66.7 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | BRAF - V600E (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | BRAF - V600E (mutation not detected) | 33.3 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12ALA (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12ALA (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12ARG (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12CYS (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12CYS (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12SER (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12VAL (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY12VAL (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Prostate Cancer - Arm A | KRAS - GLY13ASP (mutation not detected) | 100.0 Percentage of Participants |
Secondary
Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B
Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP.
Time frame: Baseline
Population: The molecular profiling tumor analysis set was defined as all enrolled participants who start treatment and had baseline archived tumor biopsy formalin fixed paraffin embedded (FFPE) sample (or fresh FFPE if archived was not available) successfully analyzed for at least one of the selected biomarkers.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | BRAF - BRAF mutaion status (mutation not detected) | 28.6 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | BRAF - V600E (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | BRAF - V600E (mutation not detected) | 71.4 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12ALA (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12ALA (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12ARG (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12CYS (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12CYS (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12SER (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12VAL (mutation detected) | 14.3 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY12VAL (mutation not detected) | 85.7 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Transitional Cell Carcinoma - Arm B | KRAS - GLY13ASP (mutation not detected) | 100.0 Percentage of Participants |
Secondary
Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B
Biopsies were obtained at screening and after drug administration. These samples were analyzed predominantly for phosphoprotein biomarkers indicative of pathway modulation, or for genetic markers correlated to drug sensitivity (eg, emerging KRAS mutation and BRAF mutation). BRAF mutation categories included BRAF mutation status and V600E. KRAS mutation categories included GLY12ALA, GLY12ARG, GLY12ASP, GLY12CYS, GLY12SER, GLY12VAL and GLY13ASP.
Time frame: Baseline
Population: The molecular profiling tumor analysis set was defined as all enrolled participants who started treatment and had baseline archived tumor biopsy formalin fixed paraffin embedded (FFPE) sample (or fresh FFPE if archived was not available) successfully analyzed for at least one of the selected biomarkers.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | BRAF - BRAF mutaion status (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | BRAF - BRAF mutaion status (mutation not detected) | 38.5 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | BRAF - V600E (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | BRAF - V600E (mutation not detected) | 38.5 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12ALA (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12ALA (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12ARG (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12ARG (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12ASP (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12CYS (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12CYS (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12SER (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12SER (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12VAL (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY12VAL (mutation not detected) | 100.0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY13ASP (mutation detected) | 0 Percentage of Participants |
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With BRAF and KRAS Mutations in Population of Triple Negative Breast Cancer - Arm B | KRAS - GLY13ASP (mutation not detected) | 100.0 Percentage of Participants |
Secondary
Percentage of Participants With Objective Response - Arm A
Percentage of participants with objective response based on the assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm) and no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease and no new lesions.
Time frame: Baseline up to 18 months.
Population: The response analysis set included all participants who received at least one dose of study medication, had the disease under study, and who had an adequate baseline tumor assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm A | 0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm A | 40 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm A | 0 Percentage of Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm A | 66.7 Percentage of Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm A | 20 Percentage of Participants |
Secondary
Percentage of Participants With Objective Response - Arm B
Percentage of participants with objective response based on the assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm) and no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease and no new lesions.
Time frame: Baseline up to 18 months.
Population: The response analysis set included all participants who received at least one dose of study medication, had the disease under study, and who had an adequate baseline tumor assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm B | 0.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm B | 33.3 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm B | 66.7 Percentage of Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm B | 66.7 Percentage of Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm B | 33.3 Percentage of Participants |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Percentage of Participants With Objective Response - Arm B | 20.0 Percentage of Participants |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Percentage of Participants With Objective Response - Arm B | 20.0 Percentage of Participants |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Percentage of Participants With Objective Response - Arm B | 50.0 Percentage of Participants |
Secondary
Percentage of Participants With Objective Response - Arm C
Percentage of participants with objective response based on the assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm) and no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease and no new lesions.
Time frame: Baseline up to 18 months.
Population: The response analysis set included all participants who received at least one dose of study medication, had the disease under study, and who had an adequate baseline tumor assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm C | 20.0 Percentage of Participants |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm C | 25.0 Percentage of Participants |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm C | 14.3 Percentage of Participants |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm C | 0 Percentage of Participants |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Percentage of Participants With Objective Response - Arm C | 33.3 Percentage of Participants |
Secondary
Progression Free Survival - Arm B Expansion
Progression free survival (PFS) defined as the time from first dose of study treatment to date of first documentation of progression or death due to any cause, whichever occurs first. PFS was calculated as first event date minus the date of first dose of study medication plus 1 . Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was Death).
Time frame: Baseline up to 18 months.
Population: The response analysis set included all participants who received at least one dose of study medication, had the disease under study, and who had an adequate baseline tumor assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Progression Free Survival - Arm B Expansion | 4.8 month |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Progression Free Survival - Arm B Expansion | 8.5 month |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 2.05 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 2.00 hr |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 2.00 hr |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 2.00 hr |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 2.00 hr |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 2.02 hr |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | 2.01 hr |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Cisplatin IV Infusion in Combination With PF-05212384 - Plasma Platinum (Arm B) | NA hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 1.06 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 1.34 hr |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 1.03 hr |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 1.02 hr |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Administration of Docetaxel IV Infusion in Combination With PF-05212384 - Plasma Docetaxel (Arm A) | 1.13 hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 0.500 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 0.500 hr |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 0.550 hr |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 0.500 hr |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 0.675 hr |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 0.517 hr |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | 0.517 hr |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B) | NA hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 0.517 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 0.500 hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | 0.500 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | NA hr |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | 0.500 hr |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | 0.500 hr |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Dacomitinib - Plasma PF-05212384 (Arm C) | NA hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 0.517 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 0.500 hr |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 0.500 hr |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 0.517 hr |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple IV Infusion Doses of PF-05212384 in Combination With Docetaxel- Plasma PF-05212384 (Arm A) | 0.542 hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 4.08 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 6.00 hr |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 6.00 hr |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib Alone - Plasma Dacomitinib (Arm C) | 5.97 hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 1, 2, 4, 6, and 24 hours post-dose on Cycle 2 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | 6.04 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | NA hr |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | 6.00 hr |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Multiple Oral Doses of Dacomitinib in Combination With PF-05212384 - Plasma Dacomitinib (Arm C) | 5.42 hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 2, 2.5, 3, 4, 6, and 24 hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 2.08 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 2.12 hr |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 2.10 hr |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 2.00 hr |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 2.05 hr |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 2.01 hr |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | 2.00 hr |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Cisplatin Alone - Plasma Platinum (Arm B) | NA hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 1, 1.5, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 1.12 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 1.00 hr |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 1.00 hr |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 1.02 hr |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of Docetaxel Alone- Plasma Docetaxel (Arm A) | 1.05 hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 7 days prior to Cycle 1 Day 1 for Arms A and B; pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 hours post-dose 14 days prior to Cycle 1 Day 1 for Arm C.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.500 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.500 hr |
| Arm A3: 130 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.500 hr |
| Arm A4: 150 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.550 hr |
| Arm A5: 180 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.500 hr |
| Arm B1: 90 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.584 hr |
| Arm B2: 110 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.517 hr |
| Arm B3: 130 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.500 hr |
| Arm B4: 150 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.500 hr |
| Arm B5: 180 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.533 hr |
| Arm B6: 215 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.509 hr |
| Arm B7: 260 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.500 hr |
| Arm B8: 310 mg PF-05212384 + Cisplatin | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | NA hr |
| Arm C1: 90 mg PF-05212384 + 30 mg Dacomitinib | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.500 hr |
| Arm C1h: 90 mg PF-05212384 + 45 mg Dacomitinib | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.500 hr |
| Arm C2: 110 mg PF-05212384 + 30 mg Dacomitinib | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.533 hr |
| Arm C3: 130 mg PF-05212384 + 30 mg Dacomitinib | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.500 hr |
| Arm C4: 150 mg PF-05212384 + 30 mg Dacomitinib | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 Alone - Plasma PF-05212384 (Arms A, B and C) | 0.533 hr |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion)
Tmax is defined as time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 (predose Day 8) hours post-dose on Cycle 1 Day 1.
Population: All enrolled participants who started treatment and who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A1: 90 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 0.517 hr |
| Arm A2: 110 mg PF-05212384 + Docetaxel | Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Single IV Infusion Dose of PF-05212384 in Combination With Cisplatin - Plasma PF-05212384 (Arm B Expansion) | 0.600 hr |